Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

by · The Cerbat Gem

Dermata Therapeutics, Inc. (NASDAQ:DRMA – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 39,351 shares, a growth of 88.8% from the November 30th total of 20,846 shares. Currently, 4.7% of the shares of the company are short sold. Based on an average daily trading volume, of 338,017 shares, the short-interest ratio is presently 0.1 days. Based on an average daily trading volume, of 338,017 shares, the short-interest ratio is presently 0.1 days. Currently, 4.7% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dermata Therapeutics stock. Armistice Capital LLC grew its stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA – Free Report) by 1,411.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 411,000 shares of the company’s stock after acquiring an additional 383,800 shares during the quarter. Armistice Capital LLC owned about 6.81% of Dermata Therapeutics worth $444,000 at the end of the most recent quarter. 8.67% of the stock is owned by hedge funds and other institutional investors.

Dermata Therapeutics Stock Down 21.5%

Dermata Therapeutics stock traded down $0.51 during trading on Friday, hitting $1.86. The stock had a trading volume of 679,525 shares, compared to its average volume of 1,254,077. Dermata Therapeutics has a 1 year low of $1.80 and a 1 year high of $23.70. The stock’s 50 day moving average is $2.99 and its two-hundred day moving average is $4.94. The stock has a market cap of $1.92 million, a price-to-earnings ratio of -0.24 and a beta of 0.53.

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) last issued its quarterly earnings data on Friday, November 14th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Check Out Our Latest Stock Report on Dermata Therapeutics

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.

Recommended Stories